Meda Biotech

Founded in 2003, Meda Biotech is a clinical-stage biopharmaceutical company developing a new class of Hybrid water soluble drugs with unprecedented control over drug properties to maximise trafficking to disease sites, dramatically enhancing efficacy while minimising toxicities. The company has been working to commercialise a technology that could make treatment more effective and less harmful to patients, especially for the treatment of cancer, pain and inflammation. Meda Biotech is developing a pipeline of novel hybrid drugs that hold the potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular and GI disorders. Meda's lead product candidate, Mewa001 (Aspirin) is currently in Phase 1 clinical testing in cancer patients for pain and inflammation. Meda also develops Hybrid water soluble drugs in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential.